{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:40:42Z","timestamp":1780065642526,"version":"3.54.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.semarthrit.2018.05.010","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T01:30:35Z","timestamp":1527125435000},"page":"436-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Functional impairment measurement in psoriatic arthritis: Importance and challenges"],"prefix":"10.1016","volume":"48","author":[{"given":"Philip","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2018.05.010_bib1","first-page":"s216","article-title":"Psoriasis and psoriatic arthritis overview","volume":"22","author":"Menter","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriaticarthritis 2015 treatment recommendations for psoriaticarthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3899\/jrheum.160904","article-title":"Updating the psoriatic arthritis (PsA) Core Domain Set: a report from the PsA workshop at OMERACT 2016","volume":"44","author":"Orbai","year":"2017","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2018.05.010_bib5","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rdc.2015.07.004","article-title":"Natural history, prognosis, and socioeconomic aspects of psoriatic arthritis","volume":"41","author":"Helliwell","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/art.21177","article-title":"Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach","volume":"53","author":"Husted","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/art.22443","article-title":"A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time?","volume":"56","author":"Husted","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib11","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2012-202608","article-title":"Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis","volume":"72","author":"Tillett","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 11","key":"10.1016\/j.semarthrit.2018.05.010_bib12","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/acr.20577","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-1-20","article-title":"The Stanford Health Assessment Questionnaire: dimensions and practical applications","volume":"1","author":"Bruce","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib14","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.semarthrit.2016.05.012","article-title":"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same?","volume":"46","author":"Coates","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib17","doi-asserted-by":"crossref","first-page":"e000025","DOI":"10.1136\/rmdopen-2014-000025","article-title":"What makes psoriatic and rheumatoid arthritis so different?","volume":"1","author":"Veale","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","article-title":"Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis","volume":"45","author":"Husted","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib19","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2011-200387","article-title":"Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment","volume":"71","author":"Strand","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib20","first-page":"439","article-title":"A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis","volume":"13","author":"Husted","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib22","first-page":"1842","article-title":"Comparison of disability and quality of life in rheumatoid and psoriatic arthritis","volume":"28","author":"Sokoll","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib23","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis\/Outcome Measures in Rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis","author":"Coates","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 11","key":"10.1016\/j.semarthrit.2018.05.010_bib24","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/acr.20620","volume":"63","author":"Maska","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib25","first-page":"886","article-title":"Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification","volume":"22","author":"Blackmore","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/1756-185X.12215","article-title":"Validation of the Thai version of the Health Assessment Questionnaire for patients with psoriatic arthritis","volume":"17","author":"Katchamart","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib27","first-page":"S34","article-title":"Rasch analysis of the Health Assessment Questionnaire Disability Index in psoriatic arthritis","volume":"135","author":"Ndosi","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib28","article-title":"A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: a GRAPPA-OMERACT initiative","author":"Hojgaard","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/03009740903468982","article-title":"Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey","volume":"39","author":"Brodszky","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib30","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.22770","article-title":"Using Rasch analysis to compare the psychometric properties of the Short Form 36 physical function score and the Health Assessment Questionnaire disability index in patients with psoriatic arthritis and rheumatoid arthritis","volume":"57","author":"Taylor","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib31","first-page":"680","article-title":"The burden of psoriatic arthritis: a literature review from a global health systems perspective","volume":"35","author":"Lee","year":"2010","journal-title":"P T"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib32","first-page":"2146","article-title":"Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis","volume":"25","author":"Husted","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/art.22605","article-title":"Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning","volume":"57","author":"Stamm","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib34","first-page":"1705","article-title":"Cross cultural adaptation and validation of the Chinese Health Assessment Questionnaire for use in rheumatoid arthritis","volume":"25","author":"Koh","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1297-319X(03)00004-6","article-title":"Cross-cultural adaptation and validation of an Arabic Health Assessment Questionnaire for use in rheumatoid arthritis patients","volume":"70","author":"El Meidany","year":"2003","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib36","first-page":"946","article-title":"A modification of the Health Assessment Questionnaire for the spondyloarthropathies","volume":"17","author":"Daltroy","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11926-007-0074-2","article-title":"Axial disease in psoriatic arthritis","volume":"9","author":"Gladman","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib38","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3899\/jrheum.110392","article-title":"It\u2019s good to feel better but it\u2019s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10","volume":"38","author":"Strand","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","article-title":"Determining a minimal important change in a disease-specific Quality of Life Questionnaire","volume":"47","author":"Juniper","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib40","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient\u2019s perspective","volume":"20","author":"Wells","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib41","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3899\/jrheum.110546","article-title":"Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction","volume":"38","author":"Mease","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib42","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3899\/jrheum.090832","article-title":"Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales","volume":"37","author":"Kwok","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib43","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib44","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3899\/jrheum.170150","article-title":"Defining Outcome Measures for Psoriatic Arthritis: a report from the GRAPPA-OMERACT Working Group","volume":"44","author":"Ogdie","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib45","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3899\/jrheum.161459","article-title":"A multicenter nominal group study to rank outcomes important to patients, and their representation in existing composite outcome measures for psoriatic arthritis","volume":"44","author":"Tillett","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib46","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","article-title":"Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial","volume":"66","author":"Kavanaugh","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib47","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/ard.2006.057901","article-title":"Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial","volume":"66","author":"Gladman","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib49","first-page":"821","article-title":"Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, Phase 3 trials","volume":"14","author":"Gottlieb","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib50","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/acr.23000","article-title":"Ustekinumab treatment and improvement of physical function and health-related quality of life in patients with psoriatic arthritis","volume":"68","author":"Rahman","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib51","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1468-3083.2011.04308.x","article-title":"Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens","volume":"26","author":"Gniadecki","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib52","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3899\/jrheum.091093","article-title":"Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis","volume":"37","author":"Mease","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib53","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1185\/03007995.2010.515804","article-title":"Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial","volume":"26","author":"Kavanaugh","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib54","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3899\/jrheum.121200","article-title":"Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study","volume":"40","author":"Strand","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","article-title":"Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)","volume":"76","author":"Strand","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib56","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib58","doi-asserted-by":"crossref","first-page":"e000119","DOI":"10.1136\/rmdopen-2015-000119","article-title":"Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure","volume":"1","author":"Mease","year":"2015","journal-title":"RMD open"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib59","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib60","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/ard.2005.040196","article-title":"Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib61","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3899\/jrheum.100069","article-title":"Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study","volume":"37","author":"Gladman","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib62","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib63","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib64","first-page":"73","article-title":"Efficacy and safety of long-term infliximab therapy in moderate to severe psoriasis and psoriatic arthritis","volume":"141","author":"Bianchi","year":"2006","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib65","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3899\/jrheum.151290","article-title":"Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials","volume":"43","author":"Combe","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib66","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib67","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2018.05.010_bib68","article-title":"How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines","volume":"63","author":"Mease","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib69","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib70","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jval.2013.10.006","article-title":"From translation to version management: a history and review of methods for the cultural adaptation of the EuroQol five-dimensional questionnaire","volume":"17","author":"Rabin","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib71","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/art.1780230203","article-title":"Measuring health status in arthritis. The arthritis impact measurement scales","volume":"23","author":"Meenan","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib72","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/rheumatology\/kem364","article-title":"An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures","volume":"47","author":"Pincus","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib73","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/ard.2009.115550","article-title":"Use of \u201cspydergrams\u201d to present and interpret SF-36 health-related quality of life data across rheumatic diseases","volume":"68","author":"Strand","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib74","first-page":"511","article-title":"Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis","volume":"24","author":"Husted","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib75","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/MLR.000000000000010311","article-title":"Patient-reported functional health and well-being outcomes with drug therapy: a systematic review of randomized trials using the SF-36 health survey","volume":"52","author":"Frendl","year":"2014","journal-title":"Med Care"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib76","first-page":"1613","article-title":"Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses","volume":"35","author":"Leung","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib77","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Econ"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib78","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1524-4733.2008.00352.x","article-title":"Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available)","volume":"11","author":"Ara","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib79","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1524-4733.2008.00428.x","article-title":"Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available","volume":"12","author":"Ara","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib80","first-page":"217","volume":"26","author":"Wells","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib81","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/rheumatology\/36.7.786","article-title":"Measurement of the quality of life in rheumatic disorders using the EuroQol","volume":"36","author":"Wolfe","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib82","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s10198-014-0638-9","article-title":"EQ-5D in skin conditions: an assessment of validity and responsiveness","volume":"16","author":"Yang","year":"2015","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib83","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jval.2012.10.010","article-title":"Mapping to obtain EQ-5D utility values for use in NICE health technology assessments","volume":"16","author":"Longworth","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib84","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.1780350102","article-title":"AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire","volume":"35","author":"Meenan","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib86","first-page":"1932","article-title":"Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis","volume":"23","author":"Husted","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib87","first-page":"1015","article-title":"Validation of the revised and expanded version of the Arthritis Impact Measurement Scales for patients with psoriatic arthritis","volume":"23","author":"Husted","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib88","first-page":"751","article-title":"Comparison of the Health Assessment Questionnaire and Arthritis Impact Measurement Scale in patients with psoriatic arthritis","volume":"65","author":"Taccari","year":"1998","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib89","unstructured":"van Reenen M, Janssen B. EQ-5D-5L user guide. https:\/\/euroqol org\/wp-content\/uploads\/2016\/09\/EQ-5D-5L_UserGuide_2015 pdf [2015] [cited 2018 Feb. 19]"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib90","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/art.11417","article-title":"Assessment of patients with psoriatic arthritis: a review of currently available measures","volume":"50","author":"Gladman","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib91","article-title":"RAPID3? Aptly named!","volume":"32","author":"Berthelot","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib92","series-title":"Arthritis Care Res (Hoboken)","article-title":"Value of RAPID3 in patients with PsA: results from the TICOPA and LOPAS II databases","author":"Coates","year":"2017"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib93","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/annrheumdis-2015-eular.2381","article-title":"SAT0584 Comparative performance of RAPID3 (Routine Assessment of Patient Index Data 3) versus other composite indices in clinical trials of psoriatic arthritis","volume":"74","author":"Reddy","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib94","article-title":"Construct validity of RAPID3 for measurement of disease activity in psoriatic arthritis [abstract]","volume":"69","author":"Walsh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib95","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1097\/00005650-198903001-00018","article-title":"Generic and disease-specific measures in assessing health status and quality of life","volume":"27","author":"Patrick","year":"1989","journal-title":"Med Care"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib96","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/ard.2003.006296","article-title":"Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis","volume":"63","author":"McKenna","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib97","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","article-title":"A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative","volume":"73","author":"Gossec","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib98","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.131021","article-title":"Development and validation of a new instrument to measure health-related quality of life in patients with psoriatic arthritis: the VITACORA-19","volume":"41","author":"Torre-Alonso","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib99","first-page":"1359","article-title":"Psoriatic arthritis quality of life instrument: an assessment of sensitivity and response to change","volume":"35","author":"Healy","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009740903347975","article-title":"Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument for Sweden","volume":"39","author":"Billing","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib101","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1136\/annrheumdis-2012-eular.931","article-title":"AB0931 Validity and reliability of the Dutch version of the psoriatic arthritis quality of life (PSAQOL) questionnaire","volume":"71","author":"Wink","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib102","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12891-016-1292-4","article-title":"Adaptation of Chinese and English versions of the Psoriatic Arthritis Quality of Life (PsAQoL) scale for use in Singapore","volume":"17","author":"Leung","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib103","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib104","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/acr.22256","article-title":"Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study","volume":"66","author":"Gladman","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3899\/jrheum.160924","article-title":"The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: construct validity, reliability, and interpretability in a clinical setting","volume":"44","author":"Di Carlo","year":"2017","journal-title":"J Rheumatol"},{"issue":"Suppl 10","key":"10.1016\/j.semarthrit.2018.05.010_bib106","article-title":"Reliability and construct validity of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire-independent validation study in a UK cohort","volume":"68","author":"Holland","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib107","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2147\/TCRM.S101619","article-title":"The Psoriatic Arthritis Impact of Disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version","volume":"12","author":"Salaffi","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib108","unstructured":"GRAPPA. GRAPPA PsA Web App. Guideline Central. 2018 [cited 2018 Mar. 21]; Available from: https:\/\/psa.guidelinecentral.com"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib109","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2230.1987.tb01844.x","article-title":"Psoriasis\u2014an index of disability","volume":"12","author":"Finlay","year":"1987","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib111","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jaad.2005.10.008","article-title":"Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective","volume":"54","author":"Mease","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib112","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2340\/0001555575240243","article-title":"The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress","volume":"75","author":"Gupta","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib113","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1365-2133.2000.03418.x","article-title":"The Salford Psoriasis Index: an holistic measure of psoriasis severity","volume":"142","author":"Kirby","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib114","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2133.2003.05492.x","article-title":"Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials","volume":"149","author":"McKenna","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib115","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years","volume":"45","author":"Cella","year":"2007","journal-title":"Med Care"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib116","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jclinepi.2006.06.025","article-title":"Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS)","volume":"61","author":"Rose","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib117","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jclinepi.2013.10.024","article-title":"The PROMIS Physical Function item bank was calibrated to a standardized metric and shown to improve measurement efficiency","volume":"67","author":"Rose","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib118","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.20048","article-title":"Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population","volume":"50","author":"Krishnan","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl 11","key":"10.1016\/j.semarthrit.2018.05.010_bib119","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/acr.20575","volume":"63","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib120","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib121","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/rheumatology\/36.5.551","article-title":"Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D)","volume":"36","author":"Hurst","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib122","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3899\/jrheum.090449","article-title":"Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"37","author":"Kvamme","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib123","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib124","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jbspin.2015.06.018","article-title":"Patient global assessment in psoriatic arthritis\u2014what does it mean? An analysis of 223 patients from the Psoriatic Arthritis Impact of Disease (PsAID) study","volume":"83","author":"Talli","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1477-7525-6-75","article-title":"Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study","volume":"6","author":"Revicki","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib126","doi-asserted-by":"crossref","first-page":"R170","DOI":"10.1186\/ar2859","volume":"11","author":"Strand","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib127","series-title":"SF-36 Physical & Mental Health Summary Scales: A manual for users of version 1","author":"Ware","year":"2001"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib128","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/art.1780250903","article-title":"The arthritis impact measurement scales. Further investigations of a health status measure","volume":"25","author":"Meenan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib129","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaad.2005.03.050","article-title":"Decision points for the initiation of systemic treatment for psoriasis","volume":"53","author":"Feldman","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2018.05.010_bib130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.0022-202X.2003.09101.x","article-title":"Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis","volume":"122","author":"Sampogna","year":"2004","journal-title":"J Invest Dermatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217308004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217308004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T18:35:29Z","timestamp":1751654129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217308004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":130,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0049017217308004"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.05.010","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional impairment measurement in psoriatic arthritis: Importance and challenges","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}